Lalla Rajesh V, Peterson Douglas E
Division of Oral Medicine, Department of Oral Health and Diagnostic Sciences and the Head and Neck/Oral Oncology Program, Neag Comprehensive Cancer Center University of Connecticut Health Center, Farmington, CT 06030, USA.
Cancer J. 2006 Sep-Oct;12(5):348-54. doi: 10.1097/00130404-200609000-00004.
Mucositis is a clinically important and sometimes dose-limiting complication of cancer therapy. Mucositis lesions can be painful, affect nutrition and quality of life, lead to sepsis, and have significant economic impact. Recent modeling of the toxicity has been based on the continuum of clinical signs and symptoms of mucositis involving the alimentary tract, including both oral and gastrointestinal sites. The pathogenesis of oral and gastrointestinal mucositis is multifactorial and complex. In recent years, there has been a substantial increase in both basic and clinical research related to mucosal injury in cancer patients. Since most of this research has been directed to oral mucositis, the present review principally addresses this component of the toxicity. Morbidity, economic impact, pathogenesis and clinical course of mucositis are discussed. In addition, several agents in clinical development for mucositis are discussed in the context of the current pathobiologic model as well as the recently updated evidence-based clinical management guidelines.
黏膜炎是癌症治疗中一种具有临床重要性且有时会限制剂量的并发症。黏膜炎病变可能会引起疼痛，影响营养状况和生活质量，导致败血症，并产生重大经济影响。近期对该毒性的建模是基于涉及消化道（包括口腔和胃肠道部位）的黏膜炎临床体征和症状的连续过程。口腔和胃肠道黏膜炎的发病机制是多因素且复杂的。近年来，与癌症患者黏膜损伤相关的基础研究和临床研究都有了大幅增加。由于大部分此类研究都针对口腔黏膜炎，因此本综述主要探讨该毒性的这一组成部分。文中讨论了黏膜炎的发病率、经济影响、发病机制和临床过程。此外，还在当前病理生物学模型以及最近更新的循证临床管理指南的背景下，讨论了几种正在临床开发用于治疗黏膜炎的药物。
